MedTrace Logo

Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans

NCT05883306 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-05-31

No results posted yet for this study

Summary

To assess absorption, metabolism and excretion of \[14C\]-LXI-15028 in Chinese healthy male Subjects following a single oral dose of \[14C\]LXI-15028 suspension.

Conditions

  • Healthy Subjects
  • Pharmacokinetics of 14C-labeled of LXI-15028

Interventions

DRUG

[14C]LXI-15028

\[14C\]LXI-15028

Sponsors & Collaborators

  • Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Liyan Miu · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2022-07-21
Completion
2022-12-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05883306 on ClinicalTrials.gov